Responses
Regular and Young Investigator Award Abstracts
Clinical Trial Completed
611 XTX202–01/02–001, Phase 1/2 first-in human study of XTX202, a masked, tumor-activated IL-2βγ, in patients with advanced solid tumors: results from phase 1
Compose a Response to This Article
Other responses
No responses have been published for this article.
